LANADELUMAB REDUCES HAE ATTACK RATE: INTERIM FINDINGS FROM THE HELP OPEN-LABEL EXTENSION STUDY

被引：1
|
作者：
Riedl, M.
Bernstein, J.
Yang, W.
Longhurst, H.
Magerl, M.
Hebert, J.
Shennak, M.
Martinez-Saguer, I.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2018年 / 121卷 / 05期
关键词：
D O I：
10.1016/j.anai.2018.09.116
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P168
引用
收藏
页码：S37 / S37
页数：1
相关论文
共 50 条
  • [1] Consistent Reduction in HAE Attack Rate with Lanadelumab Regardless Of Baseline Attack Frequency: Interim Findings From the Phase 3 HELP Study Open Label Extension (OLE)
    Banerji, Aleena
    Riedl, Marc
    Tachdjian, Raffi
    Nurse, Christina
    Paes, Kim
    Li, Huamin
    Kiani-Alikhan, Sorena
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB103 - AB103
  • [2] LONG-TERM EFFICACY OF LANADELUMAB: INTERIM RESULTS FROM THE HELP OPEN-LABEL EXTENSION STUDY
    Riedl, M.
    Cicardi, M.
    Hao, J.
    Lu, P.
    Li, H.
    Manning, M.
    Bernstein, J.
    Busse, P.
    Tachdjian, R.
    Gower, R.
    Wedner, H.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S30 - S31
  • [3] Lanadelumab is well-tolerated and effective across patient subgroups: Findings from the HELP open-label extension study
    Maurer, M.
    Lumry, W. R.
    Li, H. H.
    Jacobs, J.
    Soteres, D.
    Lu, P.
    Hao, J.
    Banerji, A.
    ALLERGY, 2020, 75 : 60 - 60
  • [4] LONG-TERM LANADELUMAB TREATMENT IMPROVES HEALTH-RELATED QUALITY OF LIFE: HELP OPEN-LABEL EXTENSION STUDY INTERIM FINDINGS
    Lumry, W.
    Maurer, M.
    Magerl, M.
    Jain, G.
    Devercelli, G.
    Regnault, A.
    Meunier, J.
    Riedl, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S29 - S29
  • [5] Attack-free status during steady state of lanadelumab treatment in patients with -hereditary angioedema: findings from the HELP open-label extension study
    Magerl, M.
    Johnston, D. T.
    Lumry, W. R.
    Bernstein, J. A.
    Nurse, C.
    Yu, M.
    Riedl, M. A.
    ALLERGOLOGIE, 2022, 45 (08) : 606 - 606
  • [6] LANADELUMAB EFFICACY AFTER SWITCHING FROM PLACEBO: RESULTS FROM THE HELP AND HELP OPEN-LABEL EXTENSION STUDIES
    Tachdjian, R.
    Anderson, J.
    Busse, P.
    Johnston, D.
    Kiani, S.
    Nurse, C.
    Paes, K.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S38 - S38
  • [7] Long-term prevention of attacks with lanadelumab across subgroups of patients with hereditary angioedema (HAE): final results from the HELP open-label extension study
    Maurer, M.
    Bernstein, J. A.
    Jacobs, J.
    Lumry, W. R.
    Ren, H.
    Soteres, D.
    Yu, M.
    Martinez-Saguer, I
    ALLERGY, 2021, 76 : 10 - 10
  • [8] Long-term Impact of Lanadelumab on Patients with Hereditary Angioedema (HAE) Type 1/2: Patient Reported Outcome (PRO) Findings from the HELP Open-label Extension Study (OLE)
    Watt, Maureen
    Maurer, Marcus
    Devercelli, Giovanna
    Paes, Kim
    Regnault, Antoine
    Meunier, Julliette
    Bunod, Laurine
    Riedl, Marc
    Lumry, William
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB24 - AB24
  • [9] LONG-TERM EFFICACY AND SAFETY OF LANADELUMAB: FINAL RESULTS FROM THE HELP OPEN-LABEL EXTENSION STUDY
    Banerji, A.
    Hao, J.
    Yu, M.
    Bernstein, J.
    Johnston, D.
    Riedl, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2020, 125 (05) : S21 - S21
  • [10] Efficacy of Lanadelumab in Hereditary Angioedema Patients With and Without Prior Long-Term Prophylaxis Use: Interim Results From the HELP Open-Label Extension Study
    Paes, Kim
    Craig, Timothy
    Bernstein, Jonathan
    Longhurst, Hilary
    Aygoren-Pursun, Emel
    Nurse, Christina
    Zuraw, Bruce
    Jacobs, Joshua
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB102 - AB102
12345